Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab′ fragment by poly(ethylene glycol) (PEG) modification

British Journal of Cancer

Volumn 73, Issue 2, 1996, Pages 175-182

  Delgado, C ^a   Pedley, R B ^a   Herraez, A ^a   Boden, R ^a   Boden, J A ^a   Keep, P A ^a   Chester, K A ^a   Fisher, D ^a   Begent, R H J ^a   Francis, G E ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Immunotherapy; Pharmacokinetics; Poly(ethylene glycol) modification; Tumour targeting

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; RADIOIMMUNOTHERAPY; TISSUE SPECIFICITY;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; BIOLOGICAL AVAILABILITY; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LINEAR MODELS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; POLYETHYLENE GLYCOLS; RECOMBINANT FUSION PROTEINS; SULFONES; TISSUE DISTRIBUTION;

EID: 0030061068     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.32     Document Type: Article

References (31)

1. ARENDSHORST WJ AND NAVAR LG. (1988). Renal circulation and glomerular hemodynamics. In Diseases of the Kidney. Schrier RW and Gottschalk CW (eds) p. 65. Boston: Little, Brown.
2. BUCHEGGER F, PELEGRIN A, DELALOYE B, BISCHOF-DELALOYE A AND MACH JP. (1990). Iodone-131-labeled MAb F(ab′)2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J. Nucl. Med., 31, 1035-1044.
3. CHESTER KA, ROBSON L, KEEP PA, PEDLEY RB, BODEN JA, BOXER GM AND BEGENT RH. (1994). Production and tumour-binding characterization of a chimeric anti-CEA Fab expressed in Escherichia coli. Int. J. Cancer, 57, 67-72.
4. DELGADO C, PATEL JN, FRANCIS GE AND FISHER D. (1990). Coupling of poly(ethylene glycol) to albumin under very mild conditions by activation with tresyl chloride: characterization of the conjugate by partitioning in aqueous two-phase systems. Biotech. Appl. Biochem., 12, 119-128.
5. DELGADO C, ANDERSON RJ, FRANCIS GE AND FISHER D. (1991). Separation of cell mixtures by immunoaffinity cell partitioning: strategies for low abundance cells. Anal. Biochem., 192, 322-328.
6. DELGADO C, FRANCIS GE AND FISHER D. (1992a). Uses and properties of PEG-linked proteins. In Critical Reviews in Therapeutic Drug Carrier Systems, Bruck SD. (ed.) pp. 249-304. CRC Press: Boca Raton, FL.
7. DELGADO C, SANCHO P, MENDIETA J AND LUQUE J. (1992b). Ligand-receptor interactions in affinity cell partitioning. Studies with transferrin covalently linked to monomethoxy(polyethylene glycol) and rat reticulocytes. J. Chromatogr., 594, 97-103.
8. FISHER D, DELGADO C, MORRISON J, YEUNG G AND TILCOCK C. (1991). Pegylation of membrane surfaces. In Cell and Model Membrane Interactions, Ohki S (ed.) pp.47-62. Plenum Press: New York.
9. FISHER D, DELGADO C, TEJEDOR MC, MALIK F AND FRANCIS GE. (1995). PEG-protein constructs for clinical use. In Perspectives on Protein Engineering and Complementary Technologies, Geisow MJ (ed.) p. 223. Mayflower Worldwide Ltd: Wolverhampton.
10. FRANCIS GE, DELGADO C AND FISHER D. (1991). PEG-modified proteins. In Stability of Protein Pharmaceuticals: in vivo Pathways of Degradation and Strategies for Protein Stabilization (Pharmaceutical Biotechnology, Borchardt, R.T. Ed; Vol. 3) Ahern TJ and Manning MC (eds) p. 235. Plenum Press: New York.
11. FRANCIS GE, FISHER D, DELGADO C AND MALIK F. (1995a). Polymer modification. World Intellectual Property Organization WO 95/06058.
12. FRANCIS GE, DELGADO C, FISHER D, MALIK F AND AGRAWAL AK. (1995b). Polyethylene glycol modification: relevance of improved methodology to tumour targeting, J Drug Targeting (in press).
13. FUJIMORI K, COVELL DG, FLETCHER JE AND WEINSTEIN JN. (1989). Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors. Cancer Res., 49, 5656-5663.
14. HAGEL H. (1988). Pore size distributions. In Aqueous Size Exclusion Chromatography (J. Chromatography Library, Vol. 40), Duani PL (ed.), p. 119. Elsevier: Amsterdam.
15. JACOBY RO AND FOX JG. (1984). Biology and diseases of mice. In Laboratory Animal Medicine, Fox JG, Cohen BJ and Loew FM (eds.), Academic Press: Orlando, FL.
16. KITAMURA K, TAKAHASHI T, TAKASHINA K, YAMAGUCHI T, NOGUCHI A, TSURUMI H, TOYOKUNI T AND HAKOMORI S. (1990). Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem. Biophys. Res. Commun., 171, 1387-1394.
17. KITAMURA K, TAKAHASHI T, YAMAGUCHI T, NOGUCHI A, TAKASHINA K, TSURUMI H, INAGAKE M, TOYOKUNI T AND HAKOMORI S. (1991). Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res., 51, 4310-4315.
18. KNUSLI C, DELGADO C, MALIK F, DOMINE M, TEJEDOR MC, IRVINE AE, FISHER D AND FRANCIS GE. (1992). Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity. Br. J. Haematol., 82(4), 654-663.
19. LANE DM, EAGLE KF, BEGENT RH, HOPE-STONE LD, GREEN AJ, CASEY JL, KEEP PA, KELLY AMB, LEDERMANN JA, GLASER MG AND HILSON AJW. (1994). Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab′)2 antibodies. Br. J. Cancer, 70, 521-525.
20. MALIK F, DELGADO C, KNUSLI C, IRVINE AE, FISHER D AND FRANCIS GE. (1992). Polyethylene glycol (PEG) modified granulocyte-macrophage colony stimulating factor (GM-CSF) with conserved biological activity. Exp. Hematol., 20, 1028-1035.
21. MARTIN F, WOODLE MC, REDEMANN C AND YAU-YOUNG A. (1991). Solid tumor treatment method and composition. World Intellectual Property Organization WO 91/05546.
22. 2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br. J. Cancer, 68, 69-73.
23. PEDLEY RB, BODEN JA, BODEN R, BEGENT RH, TURNER A, HAINES AM AND KING DJ. (1994). The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br. J. Cancer, 70, 1126-1130.
24. RABKIN R AND DAHL DC. (1993). Renal uptake and disposal of proteins and peptides. In Biological Barriers to Protein Delivery, Audus KL and Raub TJ (eds) p. 299. Plenum Press: New York.
25. SMITH OP, DELGADO C, MALIK F, KNUSLI C, DOMINE M, FISHER D AND FRANCIS GE. (1991). Receptor binding studies of PEG modified GM-CSF with dissociated biological activities. Br. J. Haematol., 77 (Suppl.1), 15.
26. THOMAS GD, CHAPPELL MJ, DYKES PW, RAMSDEN DB, GODFREY KR AND ELLIS JR. (1989). Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res., 49, 3290-3296.
27. TOZER GM, SHAFFI KM, PEISE VE AND CUNNINGHAM VJ. (1994). Characterisation of tumour blood flow using a 'tissue-isolated' preparation. Br. J. Cancer, 70, 1040-1046.
28. WALTER H, BROOKS DE AND FISHER D. (Eds.) (1985). Partitioning in Aqueous Two-Phase Systems, Theory, Methods, Uses and Applications to Biotechnology. Academic Press: New York.
29. YORKE ED, BEAUMIER PL, WESSELS BW, FRITZBERG AR AND MORGAN AC, Jr. (1991). Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics. Int. J. Radiat. Appl. & Instr.-Part B, Nucl. Med. Biol., 18, 827-835.
30. YOSHIOKA H. (1991). Surface modification of haemoglobin-containing liposomes with polyethylene glycol prevents liposome aggregation in blood plasma. Biomaterials, 12, 861.
31. YUAN J. (1993). Estimation of variance for AUC in animal studies. J. Pharm. Sci., 82, 761-763.